BioRelay™ is Ennature’s solution for unlocking the potential of nature’s active compounds. Many botanical actives are poorly absorbed, or are cleared before they can act; each of its three platforms addresses one of these limits, for greater consistency, performance, and reliability.
BioRelay™ · 01
True water solutions Powered by LIMAN™
Improves the bioavailability of plant-based lipophilic actives, so they are better absorbed and deliver their health benefits.
The problem
Many lipophilic botanical compounds disperse and absorb poorly. They pass through unabsorbed, or are metabolized in the gut.
How it works
A lecithin-based coating improves dispersion and absorption, and protects the active in the gut.
What it gives
Better absorption and stability in the gut.
Used in
BioRelay™ · 02
True oil solutions Powered by SCEMOD™
Improves the dispersion of oil-soluble actives, helping the body absorb them and unlocking their potential benefits.
The problem
Oil-soluble actives are poorly absorbed into systemic circulation, so much of their benefit is missed.
How it works
A homogeneous, oil-miscible solution with a smaller particle size, for better lymphatic absorption.
What it gives
Better absorption of oil-soluble actives.
Used in
BioRelay™ · 03
Sustained release
Encapsulates actives with a short half-life in a sustained-release matrix, so they release gradually for a longer benefit.
The problem
Many actives have a short half-life and are metabolised quickly, leaving only a small window for their benefits.
How it works
The active’s release profile is modified, so it is released steadily over a longer period.
What it gives
The benefit of a single dose lasts longer.
Used in
Clinical evidence
Benefit-driven ingredient science.
Branded ingredients backed by gold-standard human clinical studies, for the health benefits they offer.
Branded ingredientThe studyClinical outcomeOnset
Ultra Low Dose CurcuminJoint health
Crossover comparative pharmacokinetic study in 14 healthy adults, against micronized curcumin extract 95% at an equal dose
Published · Current Research in Complementary & Alternative Medicine, 2023
Double-blind, randomised, single-dose, three-way crossover pharmacokinetic study in 30 participants, 300 mg each of Berbisol™, Berbisol™ Plus and conventional berberine hydrochloride
